Interview with Keith Martin, CEO, Apitope
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
Address: Bristol & Bath Science Park
Dirac Crescent
Emersons Green
Bristol
BS16 7FR
United Kingdom
Tel: +44 (0)117 370 7720
Apitope is a privately owned European biotech company developing antigen specific therapeutic peptides for the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves’ disease, Uveitis, and others.
Autoimmune disease arises from our own immune system responding incorrectly to the proteins and complex tissues that make up our body. For example, multiple sclerosis is caused by immune cells attacking the myelin sheath that insulates the neurons within nervous system including the brain and spinal cord.
Our research team is currently developing peptide based therapeutics designed to selectively suppress this aberrant interaction between immune cell and protein antigen, reinstating the body’s natural immune tolerance to the body’s own proteins.
This approach is founded on peer reviewed research demonstrating that treatment with a soluble, synthetic peptide derived from a known antigenic protein (such as myelin basic protein; a constituent of myelin) can prevent the immune system from responding to that protein as a threat.
In order to induce this process of immune-tolerance we must first identify the region within an antigen that the immune system recognises as a threat during an autoimmune disease. This region is referred to as an epitope.
However, Apitope has shown that in order for an epitope to effectively suppress disease it must behave as an Apitope® – Antigen Processing Independent epiTOPE. Our patented discovery platform enables us to efficiently identify and design these unique peptide therapeutics.
We aim to become the partner of choice for companies developing disease modifying therapies for autoimmune diseases and allergies.
Driving us towards this goal, Apitope has an highly experienced senior management team, each with a proven track record in the translation of novel therapeutics from bench to bedside.
Apitope’s most advanced product candidate, ATX-MS-1467, is undergoing Phase I trials in patients with multiple sclerosis. Our clinical development team is working in partnership with Merck-Serono, a leading company in the development and marketing of MS therapies, to move our product ahead as quickly and effectively as possible.
The company’s lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian…
UK Prime Minister Keir Starmer’s government continues its push to overhaul the country’s iconic National Health Service (NHS). After originally announcing plans to restructure NHS England, the body that manages…
Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine…
Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society, delves into the organization’s mission to transform dementia care through innovation, advocacy, and global collaboration. Carragher addresses critical challenges, including…
Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional…
The participation of Emma Walmsley, CEO of GlaxoSmithKline (GSK), in the FT Live Global Pharma and Biotech Summit coincided with the outcome of the American elections and the historic win…
A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern…
Medtech-focused recruitment consultant Ivor Campbell casts his eye over the profiles the global medtech industry needs most today. Campbell argues that while specialist scientists and engineers remain as important as…
The newly elected UK government’s Secretary of State for Health and Social Care Wes Streeting has a full plate of challenges ahead. Britain’s National Health Service (NHS) is plagued with…
Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the…
A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in…
Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it…
See our Cookie Privacy Policy Here
